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Abstract
Rapid advances in the forward engineering of genetic circuitry in living cells has positioned 
synthetic biology as a potential means to solve numerous biomedical problems, including disease 
diagnosis and therapy. One challenge in exploiting synthetic biology for translational applications 
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is to engineer microbes that are well tolerated by patients and seamlessly integrate with existing 
clinical methods. We use the safe and widely used probiotic Escherichia coli Nissle 1917 to 
develop an orally administered diagnostic that can noninvasively indicate the presence of liver 
metastasis by producing easily detectable signals in urine. Our microbial diagnostic generated a 
high-contrast urine signal through selective expansion in liver metastases (106-fold enrichment) 
and high expression of a lacZ reporter maintained by engineering a stable plasmid system. The 
lacZ reporter cleaves a substrate to produce a small molecule that can be detected in urine. E. coli 
Nissle 1917 robustly colonized tumor tissue in rodent models of liver metastasis after oral delivery 
but did not colonize healthy organs or fibrotic liver tissue. We saw no deleterious health effects on 
the mice for more than 12 months after oral delivery. Our results demonstrate that probiotics can 
be programmed to safely and selectively deliver synthetic gene circuits to diseased tissue 
microenvironments in vivo.
INTRODUCTION
The pervasive beneficial microbial species in and on the human body are important for the 
maintenance of mammalian homeostasis, as revealed by studies on the human microbiome 
(1,2). Even more remarkable, microbes are present in diverse organs and tissues previously 
thought to be sterile environments, including tumors (3, 4). Empirical studies dating back to 
the 19th century suggested that bacteria can affect tumor growth (5), and recent work has 
demonstrated that microbes directly administered intravenously can grow selectively in 
tumors without adversely affecting the health of the host (6–8). This phenomenon has been 
attributed to suppressed immune surveillance within the tumor and increased availability of 
nutrients in the necrotic tumor core, prompting the exploration of tumor-specific bacterial 
growth as a mode of cancer therapy and diagnosis (6–14). Specifically, the ability of 
bacteria to selectively home to tumors raises the possibility of using microbes as 
programmable delivery vehicles for therapeutic or diagnostic agents. Although such 
microbial approaches have, to date, been primarily limited to obligate anaerobes, common 
laboratory strains readily amenable to genetic engineering such as Salmonella typhimurium 
and Escherichia coli also home to tumors (6,15,16), potentially allowing the incorporation 
of specialized genetic circuitry to fight cancer.
Synthetic biology is an interdisciplinary engineering process in which computational 
modeling and experimental manipulation produce specified, genetically controlled behavior 
in bacteria. This forward engineering approach can generate a variety of genetic programs 
including switches, oscillators, counters, edge detectors, and biosensors (17–23). These 
successes have stimulated interest in reprogramming bacteria for biomedical applications, 
with early examples including engineered phage for biofilm dispersal (24), and commensal 
bacteria designed to combat diabetes (25), HIV (26), and cholera (27) by producing small 
molecules directly in the gastrointestinal tract.
Bacteria have a natural propensity to colonize tumor environments, and although bacteria 
have been administered safely in human clinical trials for cancer treatment, efficient tumor 
colonization requires administration of high concentrations of bacteria directly into the 
bloodstream (9, 28, 29) and therefore has a narrow therapeutic index. We sought to improve 
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tolerability of this approach by developing a method to deliver bacteria to tumors that would 
use lower concentrations of circulating bacteria. Here, we have therefore explored oral 
administration of nonvirulent probiotic strains as a path to selectively colonize tumors while 
minimizing systemic exposure. We reasoned that oral delivery could lead to the preferential 
colonization of liver tumors by allowing probiotics to follow physiological blood flow 
patterns, wherein the venous outflow from the gut is directed to the liver via the hepatic 
portal vein. We also reasoned that the liver may be an ideal organ to target with oral 
delivery, because it is the primary site of metastasis for several tumor types including 
colorectal, breast, and pancreatic (30,31).
The metastatic spread of cancer is ultimately responsible for 90% of all cancer-related 
deaths, and liver metastases represent an enormous clinical challenge, in large part because 
of their small size and multiplicity (30). However, compared to other sites of metastasis (for 
example, bone and brain), treatment options that leverage the remarkable regenerative 
capacity of the liver are advancing. Local resection, radiation, and radio frequency ablation 
are all being explored as therapeutic approaches to focal liver metastases (32,33). To date, 
patients with liver-confined colorectal metastases that undergo local therapy have 5-year 
survival rates of ~30 to 50% (34). However, only ~6% of patients ultimately undergo a 
curative resection (35), likely because of the relatively late stage of the initial detection of 
the metastases. Thus, the need for methods in addition to standard imaging modalities that 
can detect liver metastases while preserving curative treatment options is of paramount 
importance. Here, we sought to develop a simple method for oral delivery of the probiotic 
bacterium E. coli Nissle 1917 (EcN), engineered to carry specific gene circuits that enable 
tumor detection in urine, to liver metastases.
RESULTS
Designing programmable probiotics for diagnostic applications
Motivated by the need for an accessible, highly sensitive, and selective tool for detection of 
small metastases that are beyond the reach of existing diagnostic tools, we engineered a 
bacterial strain, EcN, with a series of expression cassettes. The predominant EcN platform 
used in this study, PROP-Z (programmable probiotics with lacZ; Table 1), harbors both (i) a 
genomically integrated erythromycin-resistant luxCDABE cassette (36) to generate a 
luminescent signal from endogenous production of bacterial luciferin and luciferase (36,37) 
and (ii) a pTKW106alp7A plasmid (fig. SI, constructed for this study) that provides 
kanamycin resistance, isopropyl-β-D-thiogalactopyranoside (IPTG)–inducible lacZ 
expression, and an engineered plasmid maintenance system (see below). This PROP-Z 
construct produces two important functional outputs. First, PROP-Z bacteria produce a 
luminescent signal that is detectable both in vitro and by whole-animal imaging. 
Furthermore, this signal can be discriminated from luminescence generated by luciferase 
produced in engineered mammalian cells (see Materials and Methods). Second, diverse 
products of lacZ enzymatic activity can serve as colorimetric, fluorescent, or luminescent 
readouts to indicate activity-based cleavage of engineered substrates. The output of PROP-Z 
can be controlled by providing various luciferase and lacZ substrates, and subspecies of 
PROP-Z bacteria can be engineered to regulate the expression or activity of either enzyme 
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(Table 1). For example, PROP-Z will only produce lacZ when exposed to the inducing agent 
IPTG. Specifically, we sought to develop a versatile PROP-Z platform to act as a synthetic 
diagnostic tool for the detection of liver metastasis via the urine (Fig. 1).
PROP delivered orally colonizes experimental liver metastases
To determine the efficiency with which PROP bacteria, delivered orally, can colonize liver 
metastases, we established a murine model of colorectal cancer metastases in the liver by 
surgically injecting a metastatic murine colorectal cell line (MC26-LucF) (Table 1) into the 
spleen of immunocompetent Balb/c host mice (Fig. 2A). We visualized the growth of 
individual liver metastases by magnetic resonance imaging (MRI) in the same mouse at two 
time points (14 and 17 days after injection) and quantified the distribution of tumor sizes at 
the 14-day time point in 10 mice, where the average tumor diameters were about 1.5 mm 
(Fig. 2, B and C). The growth of metastases was additionally monitored between 1 to 3 
weeks by IVIS (in vivo imaging system) after intraperitoneal injection of D-luciferin, the 
substrate for the firefly luciferase expressed by the tumor cell line (Fig. 2, D and E). When 
luminescent signals reached 1 × 109 to 5 × 109 radiance (photons s−1cm−2 sr−1), 
corresponding to average tumor diameters of ~2 to 3 mm, we orally administered PROP-Luc 
(Table 1) and observed strong bacterial-derived luminescent signals in most metastases in 
excised livers, including in tumors as small as 1 mm (Fig. 3A). In addition, we did not see 
bacterial-derived luminescent signals arising from nontumor tissue. We quantified the 
efficiency of PROP-Luc colonization and found that 88% of 83 tumor metastases, ranging 
from 1 to 8 mm in diameter, exhibited a bacteria-derived luminescent signal (Fig. 3B, fig. 
S2, and table S1). This method confirmed the presence of liver metastases and allowed their 
visualization in the entire liver by a noninvasive approach. Together, these results 
demonstrate that orally administered probiotics have the capacity to cross the 
gastrointestinal tract and colonize large and small hepatic metastases.
Oral probiotics specifically colonize multiple models of cancer and liver metastases
To test the liver specificity of colonization, we developed a quantitative PCR (qPCR)-based 
assay (fig. S3) and measured the number of orally administered PROP-Z bacteria that 
colonized host organs, including the spleen, the other major organ with known 
reticuloendothelial filtration function (38). At 24 hours after oral administration of PROP-Z, 
liver metastases contained a striking level of colonization: 5 × 106 ± 1 × 106 bacteria per 
gram of liver tissue (n = 3 livers; Fig. 3C). In contrast, PROP-Z levels in healthy spleen, 
kidneys, and liver were below the limits of detection of our qPCR assay (<500 bacteria per 
gram of tissue), even after 7 days past PROP-Z administration to allow for bacterial growth. 
We also performed colony counts of entire organs in case the colonization was lower than 
the 500 bacteria per gram detection limit, but even then could not detect evidence of PROP-
Z bacteria in any control organ tested (Fig. 3C). This absence of colonization by orally 
delivered PROP-Z was further corroborated by histological analysis of tissue sections (brain, 
spleen, liver, kidney, heart, and lung), which revealed no indication of inflammation, tissue 
damage, or cell death (fig. S4). PROP-Z-treated mice survived with no apparent adverse 
effects for at least 12 months. These findings demonstrate that oral delivery of the probiotic 
EcN is well tolerated by the host and leads to specific colonization of hepatic tumors by EcN 
without triggering systemic responses.
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Next, we sought to investigate the specificity with which PROP can colonize tumor 
microenvironments relative to other liver injury settings. Because liver fibrosis is a final end 
result to a diverse array of liver insults, we induced liver fibrosis in mice by allowing them 
to freely ingest rodent chow containing the hepatotoxin DDC (3,5-diethoxycarbonyl-l,4-
dihydrocollidine) (39). After 3 weeks, we verified the induction of liver fibrosis in tissue 
sections (Fig. 3D) and, in a parallel cohort of mice, found that orally delivered PROP-Z did 
not colonize fibrotic tissue, as measured by colony counts (Fig. 3E). Together, these data 
indicate that oral delivery of PROP-Z achieves robust and specific colonization of 
metastases while, unlike intravenous delivery, yielding minimal concentrations of bacteria in 
blood and off-target organs.
To explore the dose dependence and potential for colonization by PROP in tumors with 
different origins, we established subcutaneous tumors derived from human ovarian 
(TOV21G) and colorectal (LS174T-LucF) tumors, as well as murine colon (MC26-LucF), 
lung (393M1-LucF), and pancreatic (KBP22) tumors, the latter two derived from GEMM 
(40). To ensure that these subcutaneous tumors were exposed to similar levels of probiotic, 
we delivered a single high dose of PROP-Z (5 × 106 CFU) by systemic intravenous injection 
and observed complete colonization of subcutaneous tumors in all but the lung tumor model 
(83% colonized) (Fig. 4, A and B). To assay whether the tumors from varying genetic 
backgrounds exhibit different thresholds for colonization, we compared the dosage 
requirements for colonization after both oral administration and traditional intravenous 
delivery in two models. We administered PROP-Z intravenously to mice bearing 
subcutaneous tumors with bacterial levels ranging from 104 to 5 × 106 CFU and observed a 
dose-dependent increase in the frequency of tumor colonization in both immunocompetent 
and compromised hosts (Fig. 4, C and D). In marked contrast to intravenous delivery, we 
found that oral delivery of PROP-Z (5 × 109 CFU) at doses well above our intravenous 
concentrations foiled to colonize subcutaneous tumors (Fig. 4, C and D), but the same doses 
led to colonization of liver metastases derived from two metastatic cell lines (393M1-LucF 
and MC26-LucF). Given the ability of intravenously administered bacteria to colonize a 
range of tumor types both in animal models and in a spectrum of clinical settings (7–13,41), 
we reasoned that propensity for tumor colonization may depend more on the local 
concentration of bacteria than on the tumor type per se.
These results suggested that oral delivery results in a markedly lower circulating level of 
bacteria than intravenous delivery. To test this hypothesis, we counted the number of 
bacteria in the blood at time points between 1 and 24 hours after oral delivery of PROP-Z 
and found no evidence of circulating bacteria above our detection limit of 103 CFU/ml of 
blood. The observation that both liver metastasis models and five subcutaneous cancer 
models were susceptible to colonization is consistent with the conclusion that PROP will 
selectively colonize tumors over healthy organs in a dose-dependent manner. Collectively, 
these findings demonstrated colonization of diverse liver metastases by oral delivery of the 
probiotic EcN, suggesting that this programmable probiotic may be an appropriate vehicle 
for developing an oral, broad-spectrum diagnostic for cancers that frequently result in liver 
metastases.
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Engineered PROP-Z maintain plasmid expression and function over time
Synthetic gene circuits are often constructed on intracellular plasmids, which function well 
in the short term (Fig. 5A) but lose stability and function in stringent conditions such as 
those found in the tumor microenvironment (15,42). To design synthetic gene circuits 
suitable for use over prolonged periods, we engineered a dual-maintenance vector to ensure 
the long-term stability of our PROP platform (Fig. 5B). The first maintenance device is a 
toxin-antitoxin system that simultaneously produces a toxin (hok) and a short-lived antitoxin 
(sok), such that in the event of plasmid loss, the cell will be killed by the long-lived toxin 
(42,43). The second device, alp7, comes from the Bacillus subtilis plasmid, pLS20, and 
produces filaments that dynamically push plasmids to the poles of the cell, ensuring equal 
segregation during cell division (44). To assay the performance of our maintenance systems, 
we measured colony counts (±S-Gal) after successive subcultures in vitro, observing nearly 
complete plasmid maintenance without antibiotics in the presence of both hok and alp7 (Fig. 
5C). Additionally, enzymatic lacZ activity remained stable for at least 48 hours (Fig. 5D).
We performed further in vitro experiments under conditions characteristic of the tumor 
environment, such as low nutrient levels, pH, and oxygen concentrations (45,46). LacZ 
activity was generally maintained, though mildly reduced in each stress condition (Fig. 5E 
and fig. S5). Tumor microenvironments exhibit complex selective pressures that can only be 
partially modeled in vitro. To rapidly test maintenance constructs and measure colonization 
over time, we used a subcutaneous cancer model (nude mice, LS174T-LucF colorectal 
cancer cell line). After intravenous injection and colonization of bacteria, we found that 
when no stabilization circuits were used, less than 10% of colonized bacteria retained 
plasmids in the tumors after 24 hours (Fig. 5F). With the addition of the hok/sok 
maintenance system, 75% of PROP-Z bacteria retained their plasmids for the first 24 hours, 
followed by a decline to 45% after 72 hours. With the combination of hok/sok and alp7, 
more than 96% of PROP-Z bacteria remained intact and retained their plasmids after 72 
hours in vivo. Although alp7 was the dominant factor, the addition of hok/sok led to a 
significant increase in maintenance of colonization at 72 hours (fig. S6; P < 0.05). This 
improvement in stability likely results from the combination of pre- and postdivision 
mechanisms that promote plasmid maintenance, mirroring natural strategies used by bacteria 
(43). This fully stabilized, high-copy expression vector may prove advantageous for other in 
vivo applications.
PROP-Z-colonized tumors exhibit increased lacZ activity over time
Having established that orally delivered PROP-Z can specifically, sensitively, and stably 
colonize experimental liver metastases, we next sought to adapt this platform for use in 
metastasis detection. The basis of using PROP-Z for noninvasive detection of tumor 
metastases depends on their capacity to activate a systemically administered agent, the 
product of which will be both excreted and detectable in the urine (Fig. 1). To quantify the 
degree of amplification achieved by our diagnostic, we first performed a proof-of-concept 
study by colonizing subcutaneous tumors (nude mice, LS174T-LucF cell line) with 
intravenous injections of PROP-Z containing both of the plasmid maintenance tools 
described above. We then excised and homogenized colonized subcutaneous tumors over 
the course of 3 days and performed colorimetric assays for lacZ activity [chlorophenol red-
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β-D-galactopyranoside (CPRG) assay] at each time point After 3 days, we observed a nearly 
five times enhanced lacZ-dependent signal compared to tumors with no bacteria (Fig. 6A).
PROP-Z detects liver metastases via the urine with high specificity and sensitivity
To test the potential of our platform to serve as a urine diagnostic, we orally delivered 
PROP-Z or lacZ-deficient bacteria to immunocompetent mice bearing MC26-LucF liver 
metastases. We also administered LuGal, a soluble conjugate of luciferin and galactose. 
Here, PROP-Z bacteria can use lacZ activity to convert this substrate to luciferin, which can 
be readily detected in the urine using a luciferase assay kit. After tumor colonization, LuGal 
was administered intravenously, followed by urine collection. Testing as little as 1 µl of the 
collected urine was sufficient to elicit a positive luciferase signal, which derives from lacZ-
mediated cleavage of LuGal to release luciferin into circulation, and the subsequent 
clearance of this product by the kidney. Thus, we were able to detect the presence of 
metastatic tumors within 24 hours of oral PROP-Z administration.
In quantifying the performance by our diagnostic across multiple replicates of control 
models including healthy mice and administration of lacZ-negative bacteria (Fig. 6B), we 
measured a total in vivo signal-to-noise ratio (SNR) of about 3.6 when comparing the 
average luciferase signal yielded by PROP-Z–colonized liver metastases to control PROP-
Z–treated animals that did not bear tumors. This SNR was sufficient for intravenously 
administered CPRG substrate to achieve readily visible urinary color changes in test cases 
(Fig. 6B, inset). As further evidence of robust diagnostic performance, we observed 
consistent increases in urine luciferase measurements over time in individual mice, 
demonstrating growth of colonized PROP-Z in the entire cohort (Fig. 6C). Acquiring a 
baseline, premeasurement value allows for the calculation of signal ratios using the ratio of 
readings taken from day 1 to day 0. Use of these values greatly reduces the coefficient of 
variance (CV) between our data sets and allows for more accurate quantitation of our 
diagnostic (CV = 0.6 to 0.75 versus CV = 0.32 for the ratios; Fig. 6, B and C). Our 
diagnostic performed similarly in tumors established with several cell lines, including a 
second liver metastasis model derived from a GEMM cell line (393M1-LucF). In this 
setting, we quantified an in vivo diagnostic SNR of 4.6, a value similar to that measured in 
our syngeneic colorectal tumor hosts, indicating that diagnostic performance can be 
generalized across multiple models (Fig. 6D). Furthermore, we also observed a consistent 
increase in signal output when comparing individuals on day 1 versus day 2 in the 393M1-
LucF model, supporting the potential capacity of PROP-Z to monitor tumor burden as a 
function of time (Fig. 6D). We additionally demonstrated no significant signal resulting 
from a mock surgery [phosphate-buffered saline (PBS) was injected instead of metastasis-
forming 393M1 cells] to control for any diagnostic signal that might have arisen in response 
to any surgical trauma required to establish the tumor model (Fig. 6E). The specificity of the 
SNR in the two liver metastasis models was further supported by our failure to detect any 
significant correlation in urine signals produced after PROP-Z were delivered to control or 
liver-damaged mice in a DDC-induced fibrosis model (P = 0.9, Student’s t test; n = 4 mice 
per group).
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The most critical aspects of any diagnostic technology are its sensitivity and specificity (47–
49). To quantify the performance of our diagnostic, we performed a ROC analysis to 
compare the two most relevant treatment groups in our MC26-LucF model (oral delivery of 
PROP-Z to mice with or without liver metastases; data from Fig. 6B) (Fig. 6F). The ROC 
curve illustrates the performance of a binary classifier system as the threshold is varied 
between case and control groups, and is used as the clinical standard for determining the 
performance of candidate diagnostics. To characterize the predictive power of a diagnostic, 
typically, the AUC (area under curve) is used as a metric, such that candidate biomarkers 
that achieve a baseline AUC value of 0.5 are considered no more predictive than a random 
biomarker, whereas an AUC score of 1 represents a perfect diagnostic. Our PROP-Z models 
yield an AUC of 0.93, which is indicative of relatively low false-negative and false-positive 
rates for our tested model. Furthermore, by using the day 1/day 0 ratio (from Fig. 6C) as a 
diagnostic value, we found not only a significant reduction in variability but also an 
enhancement in the AUC (=1.0). The PROP-Z platform can achieve high sensitivity via 
signal amplification resulting from bacterial growth, high enzyme production from stable 
plasmids, and enzymatic turnover. Although traditional diagnostics are constrained by the 
limited fraction of the injected dose that reaches the site of interest (50), even small numbers 
of PROP-Z bacteria that colonize a tumor will quickly expand enough to amplify the signal, 
allowing for a detectable value that rises above the inherent in vivo background cleavage 
levels (fig. S7).
DISCUSSION
We have developed a probiotic microbial diagnostic that can sensitively, specifically, and 
safely detect the presence of hepatic tumors in two models of liver metastasis. Oral delivery 
of PROP-Z generated a high-contrast urine signal through selective expansion of the 
probiotic in liver metastases. Furthermore, we established that EcN, used in our PROP 
platform, was safe, based on its lack of colonization of healthy organs or fibrotic liver tissue 
and the feet that we noted no deleterious health effects on mice for more than 12 months 
after oral delivery. Our data suggest that the colonization of tumors is dose-dependent 
Nevertheless, the natural reticuloendothelial filtration of gut-derived venous outflow by the 
liver maximizes liver exposure to gut bacteria, and thus, orally delivered microbes 
selectively colonize liver metastases (38,51–53).
Early detection of liver metastasis is a pressing clinical need Liver cancer is prevalent and is 
difficult to detect with conventional imaging because of poor tumor-to-organ contrast. Our 
technology may be useful for detection of primary hepatocellular carcinoma in patients at 
risk for malignant transformation (for example, chronic viral hepatitis). Tumors in other 
organs that are exposed to high bacterial concentrations from the gastrointestinal tract, such 
as colorectal cancers, may also be amenable to detection with our PROP platform.
The safely of attenuated S. typhimurium bacteria has been demonstrated in clinical trials (9), 
although this finding has not yet been extended to oral delivery and engineered microbes. 
Here, we chose a host strain, EcN, which has been prescribed in humans and has an 
established safety record in clinical trials for oral delivery to gastrointestinal disorders (54). 
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One advantage in using bacterial diagnostics is their susceptibility to antibiotics, which can 
be administered to eliminate the agent (41).
Moving forward, there are many issues that must be addressed as clinical translation of the 
PROP platform is considered. For example, the selective trafficking of oral PROP to 
translocate across the gut wall and colonize liver lesions relative to the preexisting gut 
microbiome must be investigated in humans because of the many species-specific 
differences between rodents and man. Additionally, in light of emerging evidence of 
endogenous tumor microbiomes that vary with site of disease (3,55), the interaction of 
bacterial species must be examined Special attention must also be paid to the fate of PROP 
in patients who are undergoing therapy that may have immunomodulatory effects (for 
example, radiation, cytotoxic chemotherapy, and immunotherapy). Another potential 
concern is interference of PROP or the resultant inflammatory response with radiographic 
imaging or positron emission tomography surveillance studies. Last, any approach using 
engineered bacterial species in patients will require regulatory approval before becoming a 
clinical reality. In this regard the regulatory landscape that is being established for fecal 
transplantation will be beneficial (56).
Joining a list of recent next-generation diagnostics (circulating tumor cell assays, biomarker 
monitoring), PROP aims to build toward early identification of micrometastatic disease that 
may result in improved patient outcomes and decreased treatment toxicities. With a growing 
population of patients at risk of developing liver metastases (those who have undergone 
treatment for primary liver, colorectal, breast, and pancreatic tumors), a highly sensitive, 
nonsurgical, nonradioactive method for repeated monitoring may be clinically useful. PROP 
may be amenable to further engineering to allow urinalysis by low-cost paper tests (57), 
additional substrates for colorimetric or MRI-based diagnosis, endoscopic detection, and 
integration with synthetic biomarkers for cancer (58). Ultimately, complex synthetic gene 
circuits may be extended to therapeutic strategies that use self-triggered gene circuits, such 
as quorum sensing (59) or toggle switches (60), to deliver clinical payloads to tumor 
regions.
MATERIALS AND METHODS
Statistical analyses
Statistical tests were calculated in either Microsoft Excel (Student’s t test) or GraphPad 
Prism 5.0 (ANOVA, ROC). The details of the statistical tests carried out are indicated in 
respective figure legends. Where data were approximately normally distributed values were 
compared using either Student’s t test for single variable or two- or three-way ANOVA 
Approximate P values were computed for two- or three-way ANOVA (table S2). Mice were 
randomized in different groups before being assayed.
Animal models
All animal work was approved by the committee on animal care [Massachusetts Institute of 
Technology (MIT), protocol 0414-022-17]. The liver metastasis model was generated by 
injecting luciferized mouse cancer cells into surgically externalized spleens of 
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immunocompetent mice (61). After 90 s, to allow tumor cells to seed the liver, the spleen 
was removed to prevent ectopic tumor growth. The two models used were MC26-LucF cell 
line [Tanabe Laboratory, Massachusetts General Hospital (MGH); injected at 5 × 104 cells 
per 100 µl of PBS into the spleens of female Balb/c mice 6 weeks of age, Taconic] and 
393M1-LucF cell line (Jacks Laboratory, MIT; injected at 1 × 105 cells per 100 µl of PBS 
into female B6.129SF1/J mice 6 weeks of age, Jackson Laboratory). Animals were 
monitored via IVIS (IVIS 200, Caliper Life Sciences) for about 3 weeks by intraperitoneal 
injection of D-luciferin (100 µl 30 mg/ml, 15-min waiting time) until a radiance value of 
tumors reached 1 × 109 to 5 × 109 photons s−1cm−2 sr−1 for the MC26-LucF model or 0.6 × 
108 to 3 × 108 photons s−1cm−2 sr−1 for the 393M1- LucF model. For tumor xenograft 
models, cancer cell lines were inoculated subcutaneously (0.5 × 107 to 1 × 107 cells per 
flank) in female mice at 6 weeks of age. In the liver fibrosis model, FVB/NJ mice (Jackson 
Laboratory) were fed with 0.1% (w/w) DDC (Sigma) or normal rodent chow for 3 weeks 
(Research Diets), at which point colony counts on extracted livers or urine assays were 
performed.
Bacterial strains and administration
Plasmid pTKW106alp7A was constructed by adding the 3.5-kb alp7AR cassette from the B. 
subtilis plasmid pLS20 to the pTKW106 lacZ expression vector containing the hok/sok 
plasmid maintenance system (42,62). The luxCDABE cassette was genomically integrated 
into EcN with the p16Slux plasmid (36), and subsequently, these bacteria were transformed 
with the pTKW106alp7A plasmid, creating PROP-Z (Table 1). The plasmid with no 
stabilizing element (pTKW106_delhok) was created using PCR by removing the hok/sok 
region of pTKW106. The pTKW106alp7A (alone) plasmid was created using PCR by 
removing the hok/sok region of pTKW106alp7A. The pTD103luxCDABE plasmid was 
induced by 10 µM AHL (Sigma-Aldrich). Bacteria were prepared by growth in LB (Sigma-
Aldrich) and appropriate antibiotics until exponential phase, washed three times with sterile 
PBS, and then prepared at the stated concentration in sterile PBS.
IVIS imaging
To image bacterial luminescence from subcutaneous tumors, mice were anesthetized with 
isoflurane and imaged using an IVIS with an open filter and auto-exposure setting. 
Colonization of our liver metastasis model was also observed routinely using IVIS after 
explantation of livers. For quantification of the tumor size–dependent colonization of liver 
metastases, we correlated both tumor- and bacteria-derived luminescent signals by IVIS. 
The bacteria luxCDABE cassette produced a luminescent signal without provision of an 
exogenous substrate, so bacteria luminescence expression was first measured with an IVIS 
upon explantation of the liver. Next, livers were soaked in D-luciferin, which generated a 
luminescent signal derived from MC26-LucF tumors (firefly luciferase). MC26-LucF 
luciferase gave rise to radiance units of ~1 × 107 to 1 × 1010 photons s−1 cm−2 sr−1, whereas 
bacterial-derived luminescence activity led to radiance values in the range of 1 × 105 to 1 × 
107 photons s−1 cm−2 sr−2. This minimal overlap in signal intensities indicated a negligible 
contribution of bacterial luciferase activity to the readings generated by MC26-LucF 
luciferase, which allowed for both bacteria luciferase (luxCDABE) and MC26-LucF 
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luciferase (firefly) to be measured sequentially when using an open filter on the IVIS 
apparatus.
Urine assay
Mice were injected subcutaneously with 1 ml of sterile PBS, followed 1.5 hours later by 100 
µl of LuGal (0.5 mg/ml) via tail vein injection. The LuGal injection was immediately 
followed by a second subcutaneous injection of 1 ml of sterile PBS to promote urine 
production for retrieval. Mice were placed in urine collection tubes for 1 to 2 hours (58). 
One microliter of urine was tested for luciferin with a luciferase assay kit (Promega 
QuantiLum Recombinant Luciferase Kit) via luminescence in a Berthold Centro LB 960 
reader (measurements done in triplicate). LacZ cleavage values were plotted as the total 
luciferase activity (the product of luminescence multiplied by the total urine volume 
collected) with values typically in the range of 5 × 105 to 5 × 106 counts. The inset in Fig. 
6B shows an example of the urine diagnostic assay, where CPRG (0.5 mg/ml) was injected 
intravenously into an animal with high lacZ activity and an observed color change in urine 
was present (+ label). The control (− label) well represents the CPRG-prompted output of an 
animal without liver metastases that received oral PROP-Z and thus exhibited very low lacZ 
cleavage. In all urine experiments, drinking water was supplemented with IPTG at a 
concentration of 10 mM for the duration of the experiment to induce lacZ expression.
Plasmid stability and β-galactosidase activity in vitro
A strain of an E. coli lacZ mutant (Mach One, Invitrogen) was transformed with either 
pTKW106, pTKW106alp7A, or pTKW106_delhok Cultures were diluted into LB media 
(Miller, Sigma-Aldrich) supplemented with antibiotics (kanamycin, 50 µg/ml) and grown 
until an approximate optical density (OD) = 0.1. Cultures were then subcultured by diluting 
1:100 into deep 96-well plates (Corning #3600) with 500 µl of LB without antibiotics and 
grown for 24 hours. After each 24-hour period, cultures were diluted 1:10,000 and grown 
again in an additional 96-well plate for 24 hours. β-Galactosidase (lacZ) activity was 
assessed by supplying a CPRG substrate and measuring absorbance at 575 nm over a 5- to 
60-min reading frame using a Tecan i200 plate reader. In wells with more concentrated 
cultures, wells were diluted from 1 to 10× to achieve a signal that gave rise to a linear 
absorbance, and the maximum value within this range was recorded as the activity reading 
for each strain on each day. Plasmid stability was calculated by plating on LB + S-Gal and 
determining the number of white and black colonies, with the 0-hour time point representing 
the result from a pre-cultured strain grown with antibiotics. Black colonies indicate positive 
β-galactosidase activity and hence the presence of the plasmid (42). In vitro lacZ activities 
(Fig. 5D) are normalized to the 0-hour time point for each strain.
Plasmid stability in vivo
Plasmid stability and enzymatic tests were performed in 6-week-old female nude mice 
(NcrNu strain; Taconic) bearing tumors derived from a human colorectal cancer cell line, 
LS174T [American Type Culture Collection (ATCC)], that harbor a firefly luciferase 
transgene (LS174T_LucF, Table 1). Tumors were initiated by subcutaneous injection of 5 × 
106 cells in 100 µl of PBS per flank and grown for 1 to 2 weeks until they reached a size of 5 
Danino et al. Page 11
Sci Transl Med. Author manuscript; available in PMC 2015 July 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
to 10 mm. To obtain measures of plasmid stability in vivo, EcN-luxCDABE bacteria with 
pTKW plasmids were injected intravenously at a dosage of 1 × 106 bacteria, and at the 
designated time point, tumors were sterilely extracted and homogenized using a tissue 
dissociator (Miltenyi), an aliquot of which was seeded on each of LB erythromcyin (100 µg/
ml), and LB erythromycin + kanamycin plates to obtain the percent of bacteria carrying 
resistant plasmids, or measured for lacZ activity as mentioned above.
Quantification of tumor colonization in subcutaneous models
Colonization of subcutaneous tumors by the PROP-Z strain was determined by IVIS 
imaging 1 to 3 days after delivery. IVIS signals were used to observe whether a tumor-
localized luminescent signal was present, because bacteria express the luxCDABE cassette 
as a chromosomal integration. Tumors were seeded in each of the models by a subcutaneous 
injection of 5 × 106 cells per flank and allowed to reach about 3 to 7 mm in size over the 
course of 2 to 3 weeks. Six tumors were quantified in each case. The human LS174T, 
KBP22, and TOV21G cells were implanted in nude mice, MC26 cells were implanted in 
Balb/c mice, and 393M1-LucF lines were implanted in B6.129SF1/J (Jackson), all 6 weeks 
of age and female. Each of the cell lines were cultured in Eagle’s minimum essential 
medium (EMEM) (LS174T-LucF; from ATCC), RPMI (TOV21G, OVCAR8; from Gibco), 
or Dulbecco’s modified Eagle’s medium (DMEM) (KBP22, MC26-LucF, 393M1-LucF; 
from Cellgro) with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin 
(Corning).
Biodistribution experiments via qPCR and colony counts
After PROP-Z delivery, organs were harvested aseptically using surgical tools treated with a 
bead sterilizer and washed in ethanol and subsequently in sterile, DNA-free water before use 
in extracting tissues. A small tissue sample of 10 to 100 mg was excised from each organ 
and used for DNA isolated with an UltraClean Tissue & Cells DNA Isolation Kit (MoBio). 
One microliter of DNA sample was used in a subsequent qPCR experiment run according to 
the manufacturer’s parameters (Qiagen, QuantiTect SYBR Kit) on a Bio-Rad iCycler 
machine. We used specific primers for EcN (Muta 7/8) to quantify PROP-Z levels (63). 
Control curves were run for each qPCR experiment using a known amount of bacteria 
purified through the UltraClean Tissue & Cells DNA Isolation Kit. Automated Ct values 
generated from a Bio-Rad iCycler machine exhibit a linear correlation with the known 
number of bacteria across several orders of magnitude (fig. S3). Colony counts were 
obtained by excising whole organs, homogenizing in a tissue dissociator (Miltenyi), and 
plating on erythromycin to specifically detect the presence of EcN/PROP-Z. Comparisons of 
colony counting from tumors and qPCR experiments were correlated.
MRI quantification of tumor diameters
Mice were imaged using a Varian 7T/310/ASR-whole mouse MRI system (Varian/Agilent). 
OsiriX software was used to analyze images from liver metastasis-nearing mice by the Koch 
Institute Animal Imaging and Preclinical Testing staff. Tumor volumes were determined by 
identifying and enclosing tumors from each slice inside dosed polygons, then summating 
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total area for each tumor, and multiplying by the slice thickness to obtain tumor volumes. 
Tumor diameters were calculated from volumes by assuming spheres [V = 4/3 π(d/2)3].
IVIS quantification of liver metastases
We quantified the area of tumor nodules by visual inspection of the gross pathological 
specimen and then corroborated the location and size of tumor formation based on the firefly 
luciferase signal from MC26 cells in IVIS images. Some tumors were not colonized as 
observed by the presence of the firefly signal in the absence of a bacterial luminescence 
signal (fig. S2, yellow boxes, center image), but these examples were primarily restricted to 
the smallest tumors observed (Fig. 2B). Tumor areas were measured and transformed into 
linear dimensions by assuming A = π(d/2)2. The x-axis labels in the histograms represent the 
center of the bin histograms, that is, tick mark of 2, and indicate tumors in the range of 1.5 to 
2.5 mm.
Measuring PROP-Z in whole blood
Blood was collected using a cardiac puncture technique to obtain 500 µl of blood from the 
animal, diluted immediately in 4.5 ml of PBS, and then plated in the presence of 
erythromycin for counting of resistant PROP-Z colonies. In our blood count experiments, 
we orally delivered PROP-Z bacteria to healthy 6-week-old female mice and collected blood 
at 1, 3, 7, 18, and 24 hours (n = 3 per time point), which did not yield any significant 
colonization via colony counting (detection limit 103 CFU per 1 ml of blood, determined by 
a spiking bacteria into a sterile blood sample). Counts from this positive control and spiked 
bacteria into PBS were highly correlated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. PROP-Z probiotics for noninvasive cancer detection
The PROP-Z diagnostic platform is made up of probiotic EcN bacteria transformed with a 
dual-stabilized, high-expression lacZ vector as well as a genomically integrated luxCDABE 
cassette that allows for luminescent visualization without providing exogenous luciferin 
(blue). (1) PROP-Z is delivered orally. (2) Probiotics rapidly (within 24 hours) translocate 
across the gastrointestinal tract and (3) specifically amplify within metastatic tumors present 
in the liver. (4) PROP-Z expresses high levels of the enzyme lacZ (red), which can cleave 
systemically injected, cleavable substrates (green and yellow). Cleavage products of the 
substrates (yellow) filter through the renal system (5) into the urine for detection (6).
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Fig. 2. Colonization of liver metastases by orally administered probiotics
(A) Representative healthy and tumor-bearing livers from Balb/c mice, excised ~21 days 
after intrasplenic injection of MC26-LucF cells bearing a firefly luciferase transgene. Arrow, 
small tumor nodules typical of those arising in this metastasis model. Scale bar, 5 mm. (B) 
Frequency distribution of tumor diameters in mice carrying MC26-LucF liver metastases 14 
days after injection of the cells as measured by MRI. n = 10 mice, 98 tumors. (C) MRI 
images of a mouse with MC26-LucF liver metastases 14 and 17 days after injection of 
MC26-LucF cells. Yellow arrows, metastases. Scale bar, 10 mm. (D) Representative IVIS 
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images for luminescence of MC26-LucF:Balb/c liver metastasis mice monitored over 21 
days. (E) Average radiance for three mice shown as a function of time.
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Fig. 3. Colonization of liver metastases by orally delivered PROP: Quantitation and specificity
(A) Twenty-four hours after oral delivery of PROP-Luc [5 × 109 colony-forming units 
(CFU)] to Balb/c mice carrying liver metastases (at 21 days), livers were excised and 
photographed (left), imaged for bacterial luminescence with IVIS (right), and then soaked in 
luciferin to visualize tumors with active mammalian MC26-LucF–derived luminescence 
(middle). Scale bars, 10 mm. (B) Distribution of colonized and uncolonized liver metastases 
from three mouse livers. Tumor diameters and colonization were determined by overlaying 
IVIS images, as described in Materials and Methods and fig. S2. (C) PROP-Z present in 
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organs of healthy Balb/c mice (left) or liver metastases–bearing mice (right) after oral 
administration were quantified by traditional colony counting on erythromycin-LB plates 
and confirmed by a qPCR-based assay. Data represent mean colony counts from organs 
from n = 4 mice ± SEM. (D) Mice bearing DDC-induced liver injury (fibrotic damage 
visualized by a hematoxylin and eosin stain) were gavaged with 5 × 109 CFU PROP-Z. 
Excised livers were examined by IVIS. (E) Bacteria levels in liver metastases of control, 
DDC-treated animals, or Balb/c mice treated with MC26-LucF cells, as determined by 
colony counts (mean ± SEM; n = 5 each).
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Fig. 4. Colonization in tumor models and different modes of administration
(A) IVIS images showing colonization of subcutaneous human (LS174T-LucF, TOV21G) or 
mouse (MC26, KBP22,393M1-LucF) tumors by 5 × 106 CFU PROP-Z, 1 to 3 days after 
intravenous administration to immunocompetent mice. (B) Colonization was determined by 
observing flank luminescence from bacteria 1 to 3 days after bacteria administration using 
IVIS and is expressed as % tumors colonized, n = 6 tumors per cell line. (C) IVIS images of 
mice (MC26-LucF:Balb/c) intravenously injected with 104 or 5 × 106 CFU PROP-Z or 
administered with 5 × 109 CFU PROP-Z via oral gavage. (D) Colonization determined in 
two models upon oral (5 × 109) or intravenous (104 to 5 × 106) injection of PROP-Z and 
expressed as % colonized, n = 6 tumors per dosage.
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Fig. 5. Dually stabilized vector efficiently maintains PROP-Z activity in vivo
(A) Bacteria luciferase signals from a constitutive luxCDABE circuit (PROP-Luc) or an 
AHL-inducible luxCDABE circuit (PROPi-Luc) 24 hours after bacterial intravenous 
injection. (B) The dual-stabilized maintenance system ensures plasmid stability in the tumor 
environment (C and D) Bacteria were grown overnight with antibiotics (0 hours), and then 
sub-cultured without antibiotics and assayed for persistence of the lacZ plasmid by 
performing differential colony counts (black/white colonies on LB S-Gal plates) (see 
Materials and Methods) (C) and by assaying for lacZ enzymatic activity (D). au, arbitrary 
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unit Mean ± SEM; n = 4. (E) LacZ activity was assayed under reduced nutrient (glucose 
from 0.02 to 0.002%), pH, and oxygen in the presence of the lacZ inducer (1 mm of IPTG) 
or in noninducing conditions (0 mM). (F) The plasmid was measured after intravenous 
delivery of bacteria in a subcutaneous cancer model (LSI 74T-LucF, nude mice). Tumors 
were analyzed by colony counts on either plasmid-selective (kanamycin + erythromycin) or 
non–plasmid-selective plates (erythromycin only). Mean ± SEM; n = 5.
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Fig. 6. Detection of metastatic tumors by PROP-Z urine diagnostic
(A) Subcutaneous tumor homogenates (nude mice, LS174T-LucF cell line) were analyzed 
for lacZ activity on days 0,1, and 3 after intravenous injection of 5 × 106 CFU of PROP-Z 
bacteria (mean ± SEM; n = 5 each). (B) PROP-Z activity was quantified after systemic 
injection of LuGal, a lacZ substrate that when cleaved produces luciferin, which is measured 
with a subsequent urine assay for luminescence (mean ± SEM; n = 5,6, and 9). P < 0.05 
Student's t test for the +bacteria/+liver metastasis/+lacZ case against the other two cases. 
(Inset) Representative cleavage assay using a color change substrate (CPRG) for the PROP-
Z-treated mice either with or without liver metastases. (C) Paired measurements taken on 
days 0 and 1 after PROP-Z administered by gavage in individual mice. (Inset) Correlation of 
luciferase values on days 0 and 1 for each of the n = 10 mice in the cohort. (D) LacZ 
cleavage ratios shown for the 393M1-LucF liver metastasis model. Mean values ± SEM. P < 
0.0001, one-way analysis of variance (ANOVA), Bonferroni post-test resulting in significant 
(P < 0.05) differences between day 0 versus day 2 and day 1 versus day 2. (Inset) IVIS 
image showing bacterial colonization of liver metastasis. (E) Urine assay lacZ cleavage data 
obtained after PROP-Z oral delivery to test animals (+liver metastasis, +PROP-Z), two 
cohorts of control mice [(M) mock surgery with PBS injected instead of PROP-Z; +liver 
metastases, +PROP-non-lacZ], and healthy mice (−liver metastases, +PROP-Z). (F) 
Receiver operating characteristic (ROC) plot illustrates the performance of a binary 
classifier system as the threshold is varied between case (+LM) and control (−LM) groups in 
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data for (B). The area under the curve (AUC = 0.93) is a metric that characterizes the 
predictive power of the candidate diagnostic under these specific conditions.
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Table 1
Bacterial strains and mammalian cell types used in this study
AHL, N-(3-oxohexanoyl)-L-homoserine lactone; GEMM, genetically engineered mouse model.
Label Bacterial strain or
mammalian cell
Genomic/plasmids Use(s)
PROP-Z EcN luxCDABE (genomic), IPTG-inducible lacZ 
(stabilized plasmid)
Bioluminescent imaging of bacteria, urine 
diagnostic assay
PROP-Luc EcN luxCDABE (genomic), luxCDABE 
(plasmid)
Bioluminescent imaging of bacteria
PROPi-Luc EcN AHL-inducible luxCDABE (plasmid) Bioluminescent imaging of bacteria
Non-lacZ Mach One lacZΔM15 (genomic mutant) Non-lacZ control for urine diagnostic assay
MC26-LucF Metastatic colorectal 
mouse cell line
Firefly luciferase (genomic) Subcutaneous xenografts and liver metastasis 
models
LS174T-LucF Human colorectal 
adenocarcinoma cell line
Firefly luciferase (genomic) Subcutaneous xenograft models
393M1-LucF GEMM lung mouse cell 
line
Firefly luciferase (genomic) Subcutaneous xenografts and liver metastasis 
models
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